CHMP2B
Basic information
Region (hg38): 3:87227271-87255556
Links
Phenotypes
GenCC
Source:
- frontotemporal dementia and/or amyotrophic lateral sclerosis 7 (Strong), mode of inheritance: AD
- frontotemporal dementia and/or amyotrophic lateral sclerosis 7 (Moderate), mode of inheritance: AD
- amyotrophic lateral sclerosis type 17 (Moderate), mode of inheritance: AD
- amyotrophic lateral sclerosis (Supportive), mode of inheritance: AD
- frontotemporal dementia and/or amyotrophic lateral sclerosis 7 (Limited), mode of inheritance: AD
- frontotemporal dementia and/or amyotrophic lateral sclerosis 7 (Strong), mode of inheritance: AD
- frontotemporal dementia and/or amyotrophic lateral sclerosis 7 (Definitive), mode of inheritance: AD
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Frontotemporal dementia and/or amyotrophic lateral sclerosis 7; Dementia, familial, nonspecific | AD | General | Genetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testing | Neurologic | 8541850; 12451202; 16041373; 16954699; 16807408; 17956895; 20352044; 20592581; 21222599; 22422914; 23142962; 23155438 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the CHMP2B gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 18 | 22 | ||||
missense | 43 | 46 | ||||
nonsense | 3 | |||||
start loss | 1 | |||||
frameshift | 3 | |||||
inframe indel | 1 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 3 | 3 | 1 | 7 | ||
non coding | 22 | 17 | 12 | 51 | ||
Total | 0 | 1 | 74 | 38 | 15 |
Variants in CHMP2B
This is a list of pathogenic ClinVar variants found in the CHMP2B region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
3-87227318-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Jan 13, 2018) | ||
3-87227372-C-A | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Benign/Likely benign (Oct 05, 2018) | ||
3-87227379-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Jan 13, 2018) | ||
3-87227421-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Benign/Likely benign (Aug 10, 2018) | ||
3-87227485-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Jan 12, 2018) | ||
3-87227489-G-A | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Apr 27, 2017) | ||
3-87227524-T-C | not specified | Uncertain significance (Aug 26, 2022) | ||
3-87227543-G-A | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Likely benign (Mar 08, 2021) | ||
3-87227549-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 • not specified | Benign (Jan 31, 2024) | ||
3-87227550-G-A | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Dec 30, 2022) | ||
3-87227554-A-G | CHMP2B-related disorder | Uncertain significance (May 15, 2024) | ||
3-87227554-A-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Aug 19, 2022) | ||
3-87227562-T-C | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (May 22, 2023) | ||
3-87227563-T-A | Likely benign (May 18, 2018) | |||
3-87227564-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 • not specified | Benign (Mar 01, 2024) | ||
3-87227570-C-G | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Likely benign (Jul 03, 2023) | ||
3-87240690-T-G | not specified | Uncertain significance (Mar 08, 2017) | ||
3-87240692-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 • CHMP2B-related disorder | Benign (Dec 06, 2023) | ||
3-87240720-G-A | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 • CHMP2B-related disorder | Conflicting classifications of pathogenicity (Aug 05, 2023) | ||
3-87240728-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 • CHMP2B-related disorder | Conflicting classifications of pathogenicity (Sep 27, 2023) | ||
3-87240731-G-A | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Feb 14, 2023) | ||
3-87240735-C-T | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Apr 19, 2022) | ||
3-87240737-C-T | CHMP2B-related disorder | Uncertain significance (Sep 03, 2024) | ||
3-87240746-A-G | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Aug 17, 2023) | ||
3-87240749-A-G | Frontotemporal dementia and/or amyotrophic lateral sclerosis 7 | Uncertain significance (Jul 01, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
CHMP2B | protein_coding | protein_coding | ENST00000263780 | 6 | 28278 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.00000462 | 0.649 | 125656 | 0 | 92 | 125748 | 0.000366 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.339 | 103 | 113 | 0.910 | 0.00000571 | 1413 |
Missense in Polyphen | 37 | 38.594 | 0.9587 | 532 | ||
Synonymous | 0.144 | 34 | 35.1 | 0.969 | 0.00000177 | 375 |
Loss of Function | 0.980 | 10 | 14.0 | 0.717 | 8.89e-7 | 145 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000119 | 0.000119 |
Ashkenazi Jewish | 0.00526 | 0.00527 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000238 | 0.000237 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000165 | 0.000163 |
Other | 0.000326 | 0.000326 |
dbNSFP
Source:
- Function
- FUNCTION: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4.;
- Disease
- DISEASE: Frontotemporal dementia, chromosome 3-linked (FTD3) [MIM:600795]: Characterized by an onset of dementia in the late 50's initially characterized by behavioral and personality changes including apathy, restlessness, disinhibition and hyperorality, progressing to stereotyped behaviors, non-fluent aphasia, mutism and dystonia, with a marked lack of insight. The brains of individuals with FTD3 have no distinctive neuropathological features. They show global cortical and central atrophy, but no beta-amyloid deposits. {ECO:0000269|PubMed:16041373}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Amyotrophic lateral sclerosis 17 (ALS17) [MIM:614696]: An adult-onset progressive neurodegenerative disorder with predominantly lower motor neuron involvement, manifest as muscle weakness and wasting of the upper and lower limbs, bulbar signs, and respiratory insufficiency. {ECO:0000269|PubMed:16807408, ECO:0000269|PubMed:20352044}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Endocytosis - Homo sapiens (human);Necroptosis - Homo sapiens (human);Disease;Vesicle-mediated transport;Membrane Trafficking;Budding and maturation of HIV virion;Late Phase of HIV Life Cycle;HIV Life Cycle;HIV Infection;Endosomal Sorting Complex Required For Transport (ESCRT);Infectious disease
(Consensus)
Recessive Scores
- pRec
- 0.146
Intolerance Scores
- loftool
- 0.591
- rvis_EVS
- -0.16
- rvis_percentile_EVS
- 41.64
Haploinsufficiency Scores
- pHI
- 0.348
- hipred
- Y
- hipred_score
- 0.765
- ghis
- 0.573
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.922
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Chmp2b
- Phenotype
- nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- autophagy;nucleus organization;endosome organization;mitotic metaphase plate congression;regulation of centrosome duplication;protein transport;endosomal transport;macroautophagy;viral life cycle;endosome transport via multivesicular body sorting pathway;multivesicular body assembly;viral budding via host ESCRT complex;late endosome to vacuole transport;cognition;multivesicular body-lysosome fusion;midbody abscission;neuron cellular homeostasis;regulation of modification of postsynaptic structure;regulation of postsynapse organization;regulation of mitotic spindle assembly;positive regulation of viral release from host cell;ESCRT III complex disassembly
- Cellular component
- ESCRT III complex;cytoplasm;lysosome;endosome;late endosome;multivesicular body;cytosol;plasma membrane;postsynaptic density;late endosome membrane;extracellular exosome;glutamatergic synapse
- Molecular function
- protein binding;protein domain specific binding;cadherin binding